FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to the activation of helper T-cells that are specific to a WT1 peptide, and can be used in medicine to induce an immune response against a WT1-expressing malignant tumour. Method for activating helper T cells comprises bringing an antigen-presenting cell positive in at least one of HLA-DRB1*1501, HLA-DPB1*0901 and HLA-DPB1*0501, in contact with the WT1 peptide with SEQ ID NO: 2 capable of binding to the molecule HLA-DRB1*1501, HLA-DPB1*0901 and HLA-DPB1*0501.
EFFECT: invention allows obtaining helper T cells expressing a TCR-CD3 complex, which recognizes the WT1 peptide complex and HLA molecules selected from HLA-DRB1*1501, HLA-DPB1*0901 and HLA-DPB1*0501.
19 cl, 10 dwg, 4 ex
